NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia

NovaVive Inc.

NovaVive is a private Canadian immunobiology company founded in July, 2014. The Company acquired an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with regulator-approved products for cattle, horses and dogs. These products are currently sold to veterinarians in the U.S.A., Canada, Australia and New Zealand. The Company's head office is located in Belleville, Ontario, Canada.

Sign up to stay up-to-date with NovaVive news.

Recent News

MCWF Shows Promise in Controlling Mycoplasma in Dairy Cattle

NovaVive's MCWF technology has demonstrated potential to control chronic Mycoplasma bovis (M. bovis) infection in dairy cows. M. bovis causes respiratory disease, ear infection, arthritis, mastitis, abortion and other issues.

learn more

NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia

NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.

learn more

Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians

An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).

learn more

Follow NovaVive on Social Media.